Schrodinger (SDGR) Competitors $22.49 -0.54 (-2.34%) Closing price 04:00 PM EasternExtended Trading$22.92 +0.44 (+1.93%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SDGR vs. TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, CYTK, and MTSRShould you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Schrodinger vs. Its Competitors TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Metsera Schrodinger (NASDAQ:SDGR) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Which has preferable earnings and valuation, SDGR or TGTX? TG Therapeutics has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M7.95-$187.12M-$2.63-8.55TG Therapeutics$329M17.63$23.38M$0.24152.21 Is SDGR or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to Schrodinger's net margin of -83.39%. TG Therapeutics' return on equity of 18.88% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-83.39% -44.74% -26.29% TG Therapeutics 10.13%18.88%7.05% Do analysts prefer SDGR or TGTX? Schrodinger currently has a consensus price target of $32.75, suggesting a potential upside of 45.62%. TG Therapeutics has a consensus price target of $43.80, suggesting a potential upside of 19.90%. Given Schrodinger's higher possible upside, research analysts clearly believe Schrodinger is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders & institutionals have more ownership in SDGR or TGTX? 79.1% of Schrodinger shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 8.6% of Schrodinger shares are held by company insiders. Comparatively, 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, SDGR or TGTX? Schrodinger has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Does the media refer more to SDGR or TGTX? In the previous week, Schrodinger and Schrodinger both had 5 articles in the media. TG Therapeutics' average media sentiment score of 1.67 beat Schrodinger's score of 0.56 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryTG Therapeutics beats Schrodinger on 13 of the 15 factors compared between the two stocks. Get Schrodinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrodingerMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65B$2.11B$5.67B$9.50BDividend YieldN/AN/A4.05%4.00%P/E Ratio-8.5537.0527.9219.98Price / Sales7.9515.60397.1882.73Price / CashN/A54.1536.1958.45Price / Book3.899.028.635.82Net Income-$187.12M-$63.59M$3.24B$258.42M7 Day Performance3.88%3.01%3.17%1.94%1 Month Performance9.17%12.14%10.73%12.08%1 Year Performance2.98%9.69%35.04%20.90% Schrodinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrodinger2.091 of 5 stars$22.49-2.3%$32.75+45.6%+1.6%$1.65B$207.54M-8.55790Upcoming EarningsTGTXTG Therapeutics3.729 of 5 stars$38.92+5.0%$43.80+12.5%+85.5%$6.18B$329M162.17290Positive NewsNUVLNuvalent3.3182 of 5 stars$84.59+4.5%$119.60+41.4%-2.5%$6.07BN/A-19.2740Analyst ForecastLNTHLantheus4.7082 of 5 stars$83.06+2.2%$131.20+58.0%-36.5%$5.75B$1.53B23.60700Positive NewsUpcoming EarningsRYTMRhythm Pharmaceuticals3.1406 of 5 stars$89.15+2.8%$91.00+2.1%+76.3%$5.67B$130.13M-31.73140AXSMAxsome Therapeutics4.7254 of 5 stars$112.33+3.1%$172.33+53.4%+24.2%$5.53B$385.69M-19.47380Analyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ATrending NewsAnalyst RevisionCRSPCRISPR Therapeutics1.7435 of 5 stars$56.42-0.7%$71.75+27.2%+19.1%$4.87B$37.31M-12.48460Analyst ForecastAnalyst RevisionPCVXVaxcyte1.892 of 5 stars$36.38+1.3%$136.50+275.2%-56.6%$4.69BN/A-9.12160Positive NewsCYTKCytokinetics4.2357 of 5 stars$38.58+4.2%$70.92+83.8%-33.9%$4.61B$18.47M-7.29250MTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Gap Down Related Companies and Tools Related Companies TGTX Competitors NUVL Competitors LNTH Competitors RYTM Competitors AXSM Competitors TLX Competitors CRSP Competitors PCVX Competitors CYTK Competitors MTSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SDGR) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrodinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrodinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SDGR Stock Alerts